Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 47

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 47
---
     )
      
     $
     (16,622
     )
      
     $
     13,523

Net Loss

   Net loss for the three months ended March 31, 2025, was $3.1 million, compared to net loss of $16.6 million for the three months ended March 31, 2024, a decrease in net loss of $13.5 million. The change was primarily attributable to a decrease in loss from operations of $15.1 million.

Revenue

Revenue for the three months ended March 31, 2025, was $20.4 million, compared to revenue of $3.4 million for the three months ended March 31, 2024 an increase of $17.0 million. The increase was primarily due to an increase in product sales of MIPLYFFA of $17.1 million.

       30

        Cost of product revenue

        Cost of product revenue for the three months ended March 31, 2025,
         increased by approximately $1.2 million compared to the cost of product revenue for the three months ended March 31, 2024, primarily due to royalty costs related to product sales of MIPLYFFA.

     Intangible asset amortization

     Intangible asset amortization for the three months ended March 31, 2025, increased by approximately $0.1 million compared to the intangible asset amortization for the three months ended March 31, 2024, due to amortization expense related to definite-lived intangible assets acquired in the Merger
     .

Research and development

Research and development expenses decreased by $9.0 million, from $12.3 million for the three months ended March 31, 2024, to $3.3 million for the three months ended March 31, 2025. This decrease was primarily driven by a decrease in spending for the ongoing Phase 2 clinical study in KP1077 and a decrease in personnel-related costs.

Selling, general and administrative

Selling, general and administrative expenses increased by $9.6 million, from $9.9 million for the three months ended March 31, 2024, to $19.5 million